Invention Grant
- Patent Title: Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
-
Application No.: US15514416Application Date: 2015-09-22
-
Publication No.: US10144733B2Publication Date: 2018-12-04
- Inventor: Niall Andrew Anderson , Ian Baxter Campbell , Matthew Howard James Campbell-Crawford , Ashley Paul Hancock , Seble Lemma , Simon John Fawcett MacDonald , John Martin Pritchard , Panayiotis Alexandrou Procopiou
- Applicant: GlaxoSmithKline Intellectual Property Development Limited
- Applicant Address: GB Brentford, Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent Jane F. Djung; Kathryn A. Lutomski
- Priority: GB1417094.8 20140926
- International Application: PCT/EP2015/071782 WO 20150922
- International Announcement: WO2016/046230 WO 20160331
- Main IPC: C07B59/00
- IPC: C07B59/00 ; C07D471/04

Abstract:
A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.
Public/Granted literature
Information query